CSF2 and melanoma: Talimogene laherparapvec (T-VEC) is currently the only oncolytic virus to be approved for the treatment of melanoma in the United States (US) and consists of a modified herpes simplex virus type 1 (HSV-1) expressing granulocyte-macrophage colony-stimulating factor (GM-CSF).